The Landscape of Blood Cancer Research Today-and Where the Field Is Headed

Overview

Journal Blood Cancer Discov

Specialties Hematology
Oncology

Date 2021 Oct 18

PMID 34661134

Citations 9

Authors

Nicole Haloupek

Affiliations

Soon will be listed here.

Abstract

This editorial integrates the views of 's editors-in-chief and scientific editors to explore the current and near-future landscape of the study of hematologic malignancies-from the most intriguing new developments in clinical and basic research to the greatest upcoming challenges and how they will be confronted.

Citing Articles

miR-4716-3p and the target AKT2 Gene/rs2304186 SNP are associated with blood cancer pathogenesis in Pakistani population.

Nandwa J, Mehmood A, Mahjabeen I, Raheem K, Hamadou M, Raimi M Noncoding RNA Res. 2024; 9(3):695-703.

PMID: 38577021 PMC: 10990746. DOI: 10.1016/j.ncrna.2024.03.005.

Nanoparticle-Based Approaches for Treatment of Hematological Malignancies: a Comprehensive Review.

Hani U, Gowda B, Haider N, Ramesh K, Paul K, Ashique S AAPS PharmSciTech. 2023; 24(8):233.

PMID: 37973643 DOI: 10.1208/s12249-023-02670-0.

Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review.

Miranda-Galvis M, Tjioe K, Balas E, Agrawal G, Cortes J Blood Adv. 2023; 7(21):6466-6491.

PMID: 37639318 PMC: 10632659. DOI: 10.1182/bloodadvances.2023010690.

Applying CRISPR-Cas9 screens to dissect hematological malignancies.

Iyer D, Schimmer A, Chang H Blood Adv. 2022; 7(10):2252-2270.

PMID: 36355853 PMC: 10225491. DOI: 10.1182/bloodadvances.2022008966.

The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions.

Wang S, Yan X, Yang C, Naranmandura H Bioengineering (Basel). 2022; 9(11).

PMID: 36354547 PMC: 9687288. DOI: 10.3390/bioengineering9110635.